What is already known about this topic?
Obesity is a well-known risk factor for development of renal cell
carcinoma. However, the clinical importance of obesity and volumetric
body composition parameters (VBC), visceral adipose tissue (VATI),
subcutaneous adipose tissue index (SATI), in predicting survival
outcomes of metastatic renal cell carcinoma (mRCC) treated with targeted
therapy, sunitinib or pazopanib, remain to be elucidated. The present
study aimed to investigate the prognostic value of both VBC parameters
and skeletal muscle index, an indicator of sarcopenia, in mRCC patients
treated with targeted therapy.